88 related articles for article (PubMed ID: 34229447)
1. Volume increase of spleen in melanoma patients undergoing immune checkpoint blockade.
Susok L; Reinert D; Lukas C; Stockfleth E; Gambichler T
Immunotherapy; 2021 Aug; 13(11):885-891. PubMed ID: 34229447
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma.
Woo TE; Stukalin I; Ding PQ; Goutam S; Sander M; Ewanchuk B; Cheung WY; Heng DYC; Cheng T
Curr Oncol; 2023 Sep; 30(10):8936-8947. PubMed ID: 37887546
[No Abstract] [Full Text] [Related]
3. Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients.
Machado MAÁ; de Moura CS; Chan K; Curtis JR; Hudson M; Abrahamowicz M; Jamal R; Pilote L; Bernatsky S
Sci Rep; 2020 Sep; 10(1):14607. PubMed ID: 32884119
[TBL] [Abstract][Full Text] [Related]
4. Checkpoint Blockade in Melanoma Patients With Underlying Chronic Lymphocytic Leukemia.
Smithy JW; Pianko MJ; Maher C; Postow MA; Shoushtari AN; Momtaz P; Chapman PB; Wolchok JD; Park JH; Callahan MK
J Immunother; 2021 Jan; 44(1):9-15. PubMed ID: 33290361
[TBL] [Abstract][Full Text] [Related]
5. Combinational expression of tumor testis antigens NY-ESO-1, MAGE-A3, and MAGE-A4 predicts response to immunotherapy in mucosal melanoma patients.
Freiberger SN; Holzmann D; Morand GB; Hüllner M; Levesque MP; Dummer R; Koelzer VH; Rupp NJ
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5645-5653. PubMed ID: 36527482
[TBL] [Abstract][Full Text] [Related]
6. Case report: Durable complete response of a mucosal melanoma of the rectum after neoadjuvant immunotherapy with ipilimumab plus nivolumab.
Krueger O; Eisenburger R; Tasdogan A; Zimmer L; Livingstone E; Hadaschik E; Theurer S; Brodin B; Schadendorf D; Ugurel S
Front Immunol; 2024; 15():1369190. PubMed ID: 38807589
[TBL] [Abstract][Full Text] [Related]
7. A prediction model for response to immune checkpoint inhibition in advanced melanoma.
van Duin IAJ; Verheijden RJ; van Diest PJ; Blokx WAM; El-Sharouni MA; Verhoeff JJC; Leiner T; van den Eertwegh AJM; de Groot JWB; van Not OJ; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Haanen JBAG; Hospers GAP; Piersma D; van Rijn RS; van der Veldt AAM; Vreugdenhil G; Wouters MWJM; Stevense-den Boer MAM; Boers-Sonderen MJ; Kapiteijn E; Suijkerbuijk KPM; Elias SG
Int J Cancer; 2024 May; 154(10):1760-1771. PubMed ID: 38296842
[TBL] [Abstract][Full Text] [Related]
8. Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma.
Horowitch B; Lee DY; Ding M; Martinez-Morilla S; Aung TN; Ouerghi F; Wang X; Wei W; Damsky W; Sznol M; Kluger H; Rimm DL; Ishizuka JJ
Clin Cancer Res; 2023 Aug; 29(15):2908-2918. PubMed ID: 37233452
[TBL] [Abstract][Full Text] [Related]
9. Determinants of overall survival in patients with metastatic uveal melanoma.
Demkowicz P; Pointdujour-Lim R; Miguez S; Lee Y; Jones BSCL; Barker CA; Bosenberg M; Abramson DH; Shoushtari AN; Kluger H; Francis JH; Sznol M; Bakhoum MF
Cancer; 2023 Oct; 129(20):3275-3286. PubMed ID: 37382208
[TBL] [Abstract][Full Text] [Related]
10. Autoimmune retinopathy with associated anti-retinal antibodies as a potential immune-related adverse event associated with immunotherapy in patients with advanced cutaneous melanoma: case series and systematic review.
Heng JS; Kim JM; Jones DK; Stoessel KM; Weiss SA; Sznol M; Kluger HM; Walter SD; Silverstein NA; Pointdujour-Lim R
BMJ Open Ophthalmol; 2022; 7(1):e000889. PubMed ID: 35047671
[TBL] [Abstract][Full Text] [Related]
11. The effect of gastrointestinal microbiome supplementation on immune checkpoint inhibitor immunotherapy: a systematic review.
Bhatt A; Haslam A; Prasad V
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7355-7362. PubMed ID: 36928160
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant Immune Checkpoint Inhibition in Metastatic Conjunctival Melanoma.
Fan K; Waninger JJ; Yentz S; McLean S; Demirci H
Ophthalmic Plast Reconstr Surg; 2023 Sep-Oct 01; 39(5):e152-e155. PubMed ID: 37207285
[TBL] [Abstract][Full Text] [Related]
13. Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients.
Vera Aguilera J; Paludo J; McWilliams RR; Zhang H; Li Y; Kumar AB; Failing J; Kottschade LA; Block MS; Markovic SN; Dong H; Dronca RS; Yan Y
Melanoma Res; 2020 Aug; 30(4):364-375. PubMed ID: 32404734
[TBL] [Abstract][Full Text] [Related]
14. Facial palsy after administration of immune checkpoint inhibitors: case report, literature review and clinical care management.
Mezni E; Corazza G; Mari R; Coze S; Charrier N; Chanez B; Chretien AS; Rochigneux P
Front Immunol; 2024; 15():1375497. PubMed ID: 38585263
[TBL] [Abstract][Full Text] [Related]
15. Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma.
Haymaker C; Johnson DH; Murthy R; Bentebibel SE; Uemura MI; Hudgens CW; Safa H; James M; Andtbacka RHI; Johnson DB; Shaheen M; Davies MA; Rahimian S; Chunduru SK; Milton DR; Tetzlaff MT; Overwijk WW; Hwu P; Gabrail N; Agrawal S; Doolittle G; Puzanov I; Markowitz J; Bernatchez C; Diab A
Cancer Discov; 2021 Aug; 11(8):1996-2013. PubMed ID: 33707233
[TBL] [Abstract][Full Text] [Related]
16. Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma.
Grasso CS; Tsoi J; Onyshchenko M; Abril-Rodriguez G; Ross-Macdonald P; Wind-Rotolo M; Champhekar A; Medina E; Torrejon DY; Shin DS; Tran P; Kim YJ; Puig-Saus C; Campbell K; Vega-Crespo A; Quist M; Martignier C; Luke JJ; Wolchok JD; Johnson DB; Chmielowski B; Hodi FS; Bhatia S; Sharfman W; Urba WJ; Slingluff CL; Diab A; Haanen JBAG; Algarra SM; Pardoll DM; Anagnostou V; Topalian SL; Velculescu VE; Speiser DE; Kalbasi A; Ribas A
Cancer Cell; 2020 Oct; 38(4):500-515.e3. PubMed ID: 32916126
[TBL] [Abstract][Full Text] [Related]
17. Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma.
Campbell KM; Amouzgar M; Pfeiffer SM; Howes TR; Medina E; Travers M; Steiner G; Weber JS; Wolchok JD; Larkin J; Hodi FS; Boffo S; Salvador L; Tenney D; Tang T; Thompson MA; Spencer CN; Wells DK; Ribas A
Cancer Cell; 2023 Apr; 41(4):791-806.e4. PubMed ID: 37037616
[TBL] [Abstract][Full Text] [Related]
18. Current Status and Molecular Mechanisms of Resistance to Immunotherapy in Oral Malignant Melanoma.
Usta SZ; Uchihashi T; Kodama S; Kurioka K; Inubushi T; Shimooka T; Sugauchi A; Seki S; Tanaka S
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139110
[TBL] [Abstract][Full Text] [Related]
19. Recurrent Pericardial Effusion in a Patient With Delayed Progression of Melanoma Treated With Immune Checkpoint Inhibitors.
Valencia EA; Anumolu N; Jha P
Cureus; 2023 Oct; 15(10):e47727. PubMed ID: 38021498
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitor use, multimorbidity and healthcare expenditures among older adults with late-stage melanoma.
Rai P; Shen C; Kolodney J; Kelly KM; Scott VG; Sambamoorthi U
Immunotherapy; 2021 Feb; 13(2):103-112. PubMed ID: 33148082
[No Abstract] [Full Text] [Related]
[Next] [New Search]